An Active Pharmaceutical Ingredient (API) is the part of the drug that works. It creates the effects we want for treatment. In simple terms, an API is the core substance that makes medicines effective.
API, on the other hand, is known as the foundation of every pharmaceutical formulation. It significantly influences the drug’s safety and quality. A drug needs a high-quality API to be developed.
India is a top player in API manufacturing. It supplies 50% of the world’s generic medicines. India has a skilled workforce and offers cost-effective medication.
It also follows compliance with international regulatory standards. This allows India to play a diverse role in the global pharmaceutical ecosystem.
The manufacturing facilities have certifications from global regulatory bodies like the USFDA, WHO-GMP, and ISO. Our APIs stand out because of our industry experience, global certifications, and top-notch manufacturing.
Global Market Outlook for API Manufacturing
The global API market is projected to grow between 2024 and 2030 (due to the rising demand for generic medicines).
North America is expected to hold a dominant regional share of approximately 38–48%. The Asia-Pacific region will continue to grow in production volume.
The image shows the market growth by region from 2018 to 2030. It rises from below $200 billion in 2018 to an expected $359.5 billion by 2030.
North America remains the dominant market.Asia-Pacific shows the biggest volume growth. It is the main hub for production.Europe holds a steady market share, while MEA (Middle East & Africa) and Latin America show gradual increases.
In simple terms, the market jumps from $255.0 billion in 2024 to $270.5 billion in 2025.The global API market was worth about USD 255.0 billion in 2024. It’s expected to grow to USD 359.5 billion by 2030. This means a CAGR of 5.8% from 2025 to 2030.
Among different countries, North America was one of the top revenue-generating regions.China, on the other hand, is projected to witness the highest CAGR during the forecast period.The synthetic API segment led the market in 2024, contributing USD 191.6 billion in revenue.
The key market drivers are:
Country-to-Country API Opportunities
India–USA:
Almost 40% of U.S. generic drugs depend on Indian APIs. Indian plants also have important USFDA approvals.
India–Europe:
India provides EMA-compliant APIs that have CEP certifications. There is strong growth in APIs for oncology and cardiovascular therapies.
India–Africa:
India provides WHO-prequalified APIs. These are vital for essential medicines, especially anti-infectives and maternal healthcare.
| Region | % Share of India’s Pharma/API Exports | USD Value (May 2025) |
|---|---|---|
| USA (North America) | 34.5% | $1.712 billion |
| Europe | ~20-21% | (part of 76% combined) |
| Africa | ~14% | (within 76%) |
| Latin America (LATAM) | ~5% | (within 76%) |
| ASEAN | 4.88% | $242 million in Apr-May FY26 |
| Middle East | (Part of “NAFTA, Europe, Africa, LATAM” = 76%)~5-10% | —– |
India–LATAM:
The demand for APIs is rising in Brazil, Mexico, and Argentina. Spanish and Portuguese dossier-ready submissions support this growth.
India–ASEAN & Middle East:
Demand for Halal-certified APIs and chronic therapy sections is rising. This trend is driven by pharma MoUs and regional partnerships.
The USA accounts for nearly 34.5% of India’s pharma/API exports, valued at $1.712 billion.
In other terms, Europe contributes nearly 20–21% to India’s pharma/API exports.
Africa, on the other hand, holds around 4% share of India’s pharma/API exports.
Latin America contributes around 5%, which is also part of the 76% total export value. ASEAN countries represent 4.88% of exports, which are valued at around $242 million in April–May FY26.
Key Opportunities in API Manufacturing
Generic APIs
India holds a dominant place in producing affordable generic Active Pharmaceutical Ingredient (APIs). This is mainly for chronic disease treatments like diabetes, hypertension, and cardiovascular conditions.
Specialty APIs (HPAPIs, Oncology, Hormonal)
They represent high value in global competition. This comes from the specialized need for containment facilities.
API Intermediates
India is promoting local production of key intermediates. This aims to reduce reliance on imports through production-linked incentives.
Contract Manufacturing
Global pharma companies are outsourcing API production to India. They choose India for its flexible manufacturing capacity.
Export to Emerging Markets
Indian API exports are growing at 37% each year. Work more with regional distributors and health-focused NGOs in Africa, LATAM, and Asia.
Regulatory & Quality Assurance
API manufacturing facilities are certified by major global regulators. These include USFDA, WHO-GMP, EU-GMP, and CEP. This ensures the highest standard of compliance.
We provide complete DMF (Drug Master File) support and maintenance. This includes full traceability. Further operations follow strong SOPs. They are backed by strict in-house testing and a quality management system.
Challenges in API Manufacturing
India has strong API capabilities. However, the sector faces challenges. It relies on China for about 60% of its raw materials.
This includes CDSCO-led plant closures in 2024 and the need for more compliance.
Future Trends to Watch
The API industry is evolving at a fast pace, with AI-enabled synthesis improving efficiency. Green chemistry and continuous manufacturing are ahead of purchase for sustainable, cost-effective production.
The focus on biotech APIs and biosimilars is growing. This trend is mainly driven by advanced therapies.
Though beyond the API manufacturing scope, 3D printing is impacting pharmaceutical research in formulation accuracy and personalization.
Indian Pharmaceutical Industry Overview
Indian pharma companies are valued at around $50 billion and are projected to reach $130 billion by 2030. They are focused on innovation, exports, and healthcare demand. The API segment is set for major growth. It is expected to reach $22–25 billion by 2030.
It has support from government initiatives, global partnerships, and a drive for self-reliance.
Is API manufacturing profitable in India?
Yes, API manufacturing in India is increasing at a much faster rate, and due to –
Operating margins are improving as companies adopt advanced technologies and automation. Government programs, like the Production Linked Incentive (PLI) scheme, help long-term growth. Dedicated API parks also support this growth.
How to Start an API Manufacturing Company
Selecting your product (generic, HPAPI, intermediates) is based on the market demand and technical capability. Invest in early R&D infrastructure.
Also, build a strong Quality Management System. This will help ensure compliance while fostering innovation.
Select a location with API policy advantages. This can help you get government subsidies and logistical support.
Also, make sure to get all necessary licenses and approvals. This includes CDSCO, State FDA, and government bodies like pollution control boards. This will help you stay compliant with regulations.
What is the scope of API manufacturing in India?
India has a growing scope in API manufacturing and over 500 USFDA-approved plants. The capability is to produce more than 1,200 APIs domestically.
Demand is rising from the international market, Africa, Southeast Asia (SEA), and Latin America (LATAM). Some government programs like Make in India and Atmanirbhar Bharat are boosting growth.
They offer:
Regional Market Dynamics
India is exporting APIs to more than 100 countries and making itself the key global supplier. Some major exporters are the USA, Bangladesh, Brazil, Ghana, and Nigeria.
They reflect the strong demand across developing and emerging markets. India sits between East and West.
This unique location gives it a strong edge for trade. It allows for well-organized delivery to many global regions.
Innovation & Research in API Manufacturing
Research and innovation help lower production costs and improve process efficiency in API manufacturing.
Advancements in process chemistry enable cleaner, faster, and more scalable synthesis methods.
Further, government funding schemes are supporting R&D in emerging areas like-
Customization and Flexibility
Giving a custom API grade is key to meeting various regulatory and formulation standards. Since Indian manufacturers offer flexible batch size production, this in turn caters to the need for both small and large-scale requirements.
The demand for tech transfer and long-term CDMO is rising. So, collaboration and flexibility are now key differentiators in the global API market.
Conclusion
India is rapidly emerging as one of the global powerhouses in API manufacturing. This is supported by strong infrastructure, skilled talent, and government support.
The biggest opportunity lies in regulatory compliance, tech advancements, and strategic partnerships.
Now is a great time for businesses to invest in India’s growing API sector. Supportive policies are on the rise, making it even more appealing.